PolitiKit

Consultant In effect since Aug 5, 2026

Consultant Manuela Boeira of Bluesky Strategy Group Inc.

Consultant lobbyists

• Manuela Boeira Former public office holder

  Formerly Junior Research Analyst, Settlement and Integration Policy Branch, Immigration, Refugees and Citizenship Canada (2020–2020)

Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Atlantic Canada Opportunities Agency (ACOA), Business Development Bank of Canada (BDC), Canada Economic Development for Quebec Regions, Canada Pension Plan Investment Board, Canada Revenue Agency (CRA), Canadian Food Inspection Agency (CFIA), Canadian Institutes of Health Research (CIHR), Employment and Social Development Canada (ESDC), Environment and Climate Change Canada (ECCC), Export Development Canada (EDC), Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Fisheries and Oceans Canada (DFO), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Immigration, Refugees and Citizenship Canada (IRCC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), National Research Council (NRC), Natural Resources Canada (NRCan), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Social Sciences and Humanities Research Council (SSHRC), Statistics Canada (StatCan), Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (23)Hide details

• Clarify the administration of Scientific Research & Experimental Development (SR&ED) program to ensure clinical trials and international research conducted in Canada qualifies as eligible expenses
• SUBMISSION REVIEW PROCESS FOR BIOLOGICS, COST RECOVERY REVIEW to ensure Canada remains competitive overall and any new costs do not put biologics at a comparative disadvantage
• REGULATORY APPROVAL PROCESS FOR PLANTS WITH NOVEL TRAITS as NOVEL FOODS or INDUSTRIAL BIO-PRODUCTS in respect of an efficient science-based approach and allows for greater cooperation among and between government departments
• INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via the Comprehensive Economic and Trade Agreement negotiations)
• BIOSAFETY PROTOCOL in respect of Canada's participation in global discussions to ensure an enabling environment for safe new technologies
• ACCESS & BENEFIT SHARING: TRIPS AGREEMENT in respect of protecting intellectual property and preventing increased uncertainty
• Vaccine Funding - National Immunization Strategy - maintain federal leadership in providing provinces with funding for new vaccines
• VACCINE CONTRACTING AND SUPPLY to support the implementation of the federal biomanufacturing strategy, regulation of vaccines for Canadians, address immunization gaps, provide updated and timely information about vaccine development pipeline, support procurement of vaccines
• RESEARCH & DEVELOPMENT (R&D) to ensure Canadian capacity in key sectors including biomanufacturing, life sciences, and biotechnology.
• Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
• PATENTED MEDECINES PRICES REVIEW BOARD (PMPRB) PRICE REVIEW to ensure new guidelines and directives do not create disincentives for the introduction of new treatments in Canada
• ORPHAN PRODUCTS to establish formal regulations, policies or programs to encourage the research, development and introduction of new technologies to treat "orphan" or neglected diseases
• NOVEL FOODS in respect of maintaining a science-based regulatory system for novel foods derived from plant and animal biotechnology
• IMPROVEMENTS TO THE Scientific Research & Experimental Development TAX CREDITS
• Free trade agreements as they relate to the biopharmaceutical industry.
• FOOD LABELLING in respect of mitigating the unnecessary introduction of new labelling requirements for products already approved under current regulated process and in respect of maintaining harmonization of requirements with trading nations
• FOOD AND DRUGS ACT AND REGULATIONS in respect of streamlining regulatory burden and ensuring appropriate climate for the introduction of new technologies
• Establish accountability with the federally established Canadian Drug Agency (formerly Canadian Agency for Drugs and Technologies and Health) (CADTH) and its Common Drug Review process (Health Canada)
• Creation of a modern policy environment that recognizes international standards and reviews, and establishes clarity on data ownership for intellectual property
• Canadian Government investments as they relate to the biopharmaceutical industry.
• CANADIAN ENVIRONMENTAL PROTECTION ACT AND REGULATIONS in respect of modern, science-based regulations to reflect rapidly changing new technologies
• Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry.
• ADVENTITIOUS PRESENCE POLICY in respect of new agricultural biotechnology products

Registration 953973-378825-2. Look it up in the official Registry